Practical Application of Real-World Evidence in Developing Cancer Therapies

Overview

Journal JCO Clin Cancer Inform

Specialty Medical Informatics

Date 2019 Jul 24

PMID 31335165

Citations 5

Authors

Marjorie G Zauderer

Affiliations

Soon will be listed here.

Citing Articles

External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations.

Silva P, Janjan N, Ramos K, Udeani G, Zhong L, Ory M Front Med (Lausanne). 2023; 10:1198088.

PMID: 37484840 PMC: 10359981. DOI: 10.3389/fmed.2023.1198088.

Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer.

Li Y, Li C, Jiang Y, Han X, Liu S, Xu X J Oncol. 2022; 2022:1763778.

PMID: 35444698 PMC: 9015849. DOI: 10.1155/2022/1763778.

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.

Assie J, Crepin F, Grolleau E, Canellas A, Geier M, Grebert-Manuardi A Cancers (Basel). 2022; 14(6).

PMID: 35326648 PMC: 8946798. DOI: 10.3390/cancers14061498.

Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis.

Mencoboni M, Ceppi M, Bruzzone M, Taveggia P, Cavo A, Scordamaglia F Cancers (Basel). 2021; 13(6).

PMID: 33808533 PMC: 8003199. DOI: 10.3390/cancers13061388.

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.

Ibragimova K, Geurts S, Croes S, Erdkamp F, Heijns J, Tol J Breast Cancer Res Treat. 2021; 188(2):571-581.

PMID: 33743103 PMC: 8260428. DOI: 10.1007/s10549-021-06178-8.

References

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Gandhi L, Garassino M . Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2018; 379(11):e18. DOI: 10.1056/NEJMc1808567. View

Stewart M, Norden A, Dreyer N, Joe Henk H, Abernethy A, Chrischilles E . An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. JCO Clin Cancer Inform. 2019; 3:1-15. PMC: 6873914. DOI: 10.1200/CCI.18.00155. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Arbour K, Mezquita L, Long N, Rizvi H, Auclin E, Ni A . Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(28):2872-2878. DOI: 10.1200/JCO.2018.79.0006. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Corrigan-Curay J, Sacks L, Woodcock J . Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. JAMA. 2018; 320(9):867-868. DOI: 10.1001/jama.2018.10136. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

10.

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. DOI: 10.1016/S0140-6736(16)00587-0. View

11.

Nabhan C, Klink A, Prasad V . Real-world Evidence-What Does It Really Mean?. JAMA Oncol. 2019; 5(6):781-783. DOI: 10.1001/jamaoncol.2019.0450. View

12.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

13.

Unger J, Cook E, Tai E, Bleyer A . The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book. 2016; 35:185-98. PMC: 5495113. DOI: 10.1200/EDBK_156686. View

14.

Makady A, de Boer A, Hillege H, Klungel O, Goettsch W . What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews. Value Health. 2017; 20(7):858-865. DOI: 10.1016/j.jval.2017.03.008. View